Cancer of the liver, pancreas, gall bladder and bile duct

In July, all HPB and hepatology clinical and academic services, including pancreatic cancer services, transferred from University College London Hospitals NHS Foundation Trust to join the existing service at the Royal Free Hampstead NHS Trust, creating one of the largest centres in Europe for the treatment of conditions of the liver, pancreas and biliary system. This is the culmination of nearly a year's work of collaboration and integration by teams at both trusts.

All hepatology inpatient and outpatient services have transferred to the Royal Free. Inpatient HPB services have also transferred to the Royal Free, with the exception of Viral Hepatology outpatient clinics which are still held at UCLH.

UCLH retains its medical pancreato-biliary service and surgical outpatients service.

The Royal Free is now the sole specialist provider of surgical treatment for malignant and benign disease of the pancreas, liver and biliary system in the sector, serving the North London and Mount Vernon cancer networks. In addition, the Royal Free is the acute hub for HPB and hepatology conditions.

To ensure continuity of service, the Royal Free will continue to have input on relevant wards at UCLH on a daily basis.

Additionally, the academic departments previously based on the Bloomsbury campus at UCL have been integrated into the Hampstead campus. The integration of unified academic and clinical services brings unparralleled opportunities for research, development and innovation.

Benign and malignant pancreatic disease (including pancreatitis and pancreatic tumours), benign and malignant liver disease (HCC, colorectal metastases), benign and malignant gall bladder and bile duct disease.